{"url_path":"/sec/hsic/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-24","source_url":"https://www.sec.gov/Archives/edgar/data/1000228/0001000228-26-000013-index.html","accession_number":"0001000228-26-000013","cik":"0001000228","ticker":"HSIC","issuer_name":"HENRY SCHEIN INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1000228/0001000228-26-000013-index.html","primary_entity_key":"0001000228","primary_entity_name":"HENRY SCHEIN INC"},"word_count":740,"has_tables":false,"body_markdown":"ITEM 5.\n\nMarket for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of\n\nEquity Securities\n\nOur common stock is traded on the Nasdaq Global Select Market tier of\n\nthe Nasdaq Stock Market, or Nasdaq,\n\nunder the symbol HSIC.\n\nOn February 17, 2026, there were approximately 251 holders of record\n\nof our common stock and the last reported\n\nsales price was $77.21.\n\nA substantially greater number of holders of our common\n\nstock are “street name” or\n\nbeneficial holders, whose shares are held by banks, brokers and other financial\n\ninstitutions.\n\nPurchases of Equity Securities by the Issuer\n\nOur share repurchase program, announced on March 3, 2003, originally\n\nallowed us to repurchase up to two million\n\nshares pre-stock splits (eight million shares post-stock splits) of our common\n\nstock, which represented\n\napproximately 2.3% of the shares outstanding at the commencement\n\nof the program.\n\nSubsequent additional\n\nincreases since 2003 that have aggregated to an additional $6.7 billion,\n\nauthorized by our Board, to the repurchase\n\nprogram provide for a total of $6.8 billion (including $500 million authorized\n\non January 27, 2025 and an\n\nadditional $750 million authorized on September 8, 2025) of shares of our common\n\nstock to be repurchased under\n\nthis program, with $780 million currently available for future share repurchases.\n\nOn May 19, 2025, we executed an accelerated share repurchase program\n\nto repurchase a total of $250 million of\n\nour outstanding common stock based on volume-weighted average\n\nprices.\n\nIn May 2025 we received 3,122,832\n\nshares at an estimated fair value of $224 million.\n\nIn July 2025, we received an additional 368,651 shares at an\n\nestimated fair value of $26 million, representing the final amount of shares\n\nto be received under this accelerated\n\nshare repurchase program.\n\nAs of December 27, 2025, we had repurchased approximately $6.0\n\nbillion of common stock (107,876,628) shares\n\nunder these initiatives,\n\nwith $780 million available for future common stock share repurchases.\n\nThe following table summarizes repurchases of our common stock\n\nunder our stock repurchase program during the\n\nfiscal quarter ended December 27, 2025:\n\nTotal Number\n\nMaximum Number\n\nTotal\n\nof Shares\n\nof Shares\n\nNumber\n\nAverage\n\nPurchased as Part\n\nthat May Yet\n\nof Shares\n\nPrice Paid\n\nof Our Publicly\n\nBe Purchased Under\n\nFiscal Month\n\nPurchased (1)\n\nPer Share\n\nAnnounced Program\n\nOur Program (2)\n\n9/28/2025 through 11/1/2025\n\n1,020,000\n\n$\n\n64.28\n\n1,020,000\n\n14,467,711\n\n11/2/2025 through 11/29/2025\n\n488,067\n\n70.55\n\n488,067\n\n11,799,992\n\n11/30/2025 through 12/27/2025\n\n1,304,805\n\n76.64\n\n1,304,805\n\n10,244,654\n\n2,812,872\n\n2,812,872\n\n(1)\n\nAll repurchases were executed in the open market under our existing publicly announced authorized program.\n\n(2)\n\nThe maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the\n\nclosing price of our common stock at that time.\n\nThis table excludes shares withheld from employees to satisfy minimum tax\n\nwithholding requirements for equity-based transactions.\n\nDividend Policy\n\nWe have not declared any cash or stock dividends on our common stock during fiscal years 2025 or 2024.\n\nWe\n\ncurrently do not anticipate declaring any cash or stock dividends on our common\n\nstock in the foreseeable future.\n\nWe intend to retain earnings to finance the expansion of our business and for general corporate purposes, including\n\nour share repurchase program.\n\nAny declaration of dividends will be at the discretion of our Board and\n\nwill depend\n\nupon the earnings, financial condition, capital requirements, level\n\nof indebtedness, contractual restrictions with\n\nrespect to payment of dividends and other factors.\n\n[Table of Contents](#a296)\n\n[Index to Financial Statements](#a33909)\n\n47\n\n$50\n\n$100\n\n$150\n\n$200\n\n$250\n\nDecember 2020\n\nDecember 2021\n\nDecember 2022\n\nDecember 2023\n\nDecember 2024\n\nDecember 2025\n\nHenry Schein, Inc.\n\nDow Jones US Health Care Index\n\nNASDAQ Composite Index\n\nStock Performance Graph\n\nThe graph below compares the cumulative total stockholder return\n\non $100 invested, assuming the reinvestment of\n\nall dividends, on December 26, 2020, the last trading day before the\n\nbeginning of our 2021 fiscal year, through the\n\nend of our 2025 fiscal year with the cumulative total return on $100 invested\n\nfor the same period in the Dow Jones\n\nU.S. Health Care Index and the Nasdaq Stock Market Composite Index.\n\nCOMPARISON OF 5-YEAR CUMULATIVE TOTAL\n\nRETURN\n\nASSUMES $100 INVESTED ON DECEMBER 26, 2020\n\nASSUMES DIVIDENDS REINVESTED\n\nDecember 26,\n\nDecember 25,\n\nDecember 31,\n\nDecember 30,\n\nDecember 28,\n\nDecember 27,\n\n2020\n\n2021\n\n2022\n\n2023\n\n2024\n\n2025\n\nHenry Schein, Inc.\n\n$\n\n100.00\n\n$\n\n113.81\n\n$\n\n121.30\n\n$\n\n114.96\n\n$\n\n106.92\n\n$\n\n115.57\n\nDow Jones U.S. Health\n\nCare Index\n\n100.00\n\n124.30\n\n119.60\n\n121.86\n\n126.18\n\n144.40\n\nNASDAQ Stock Market\n\nComposite Index\n\n100.00\n\n123.04\n\n82.97\n\n120.01\n\n158.80\n\n191.20"}